PELOBIOTECH GmbH, a leader in the field of biotechnology, announces a strategic partnership with HVD Life Science Vertriebs GmbH to distribute the innovative Poietis’ Next-Gen Bioprinting platform, NGB-RTM in Germany.
This strategic partnership is anticipated to set new standards in the field of biotechnological research, providing scientists and researchers in Germany with access to state-of-the-art bioprinting technology. The Poietis’ NGB-R™ platform is expected to play a crucial role in advancing research in tissue engineering, regenerative medicine, and drug discovery, among other areas.
Dr. Peter Frost, CEO of PELOBIOTECH, expressed his passion for the partnership, stating, “Our alliance with HVD Life Science Vertriebs GmbH represents a significant leap forward not only for our two companies but for the entire field of biotechnological research in Germany. The Poietis’ NGB-RTM platform is at the top of bioprinting technology, enabling the creation of complex tissue structures with incredible precision. This technology has the potential to revolutionize fields from pharmaceutical testing to regenerative medicine.”
Echoing Dr. Frost's sentiments, Dr. Lothar Steeb, CEO & CSO of PELOBIOTECH, highlighted the impact this partnership would have on scientific discovery and innovation. “The distribution of Poietis’ NGB-RTM platform through our partnership, enables this revolutionary technology to be made available to innovative and outstanding researchers in Germany," said Dr. Steeb. "We are proud to contribute to the acceleration of research breakthroughs that can lead to major advances in healthcare and treatment modalities."
Werner Buergler, Sales Director of HVD Life Science Vertriebs GmbH, also commented on the new partnership, emphasizing the significance of bringing such advanced technology to the German market. “Our collaboration with PELOBIOTECH marks a pivotal moment in our mission to supply the scientific community with the most innovative and impactful technologies,” said Werner Buergler. “The Poietis’ Next-Gen Bioprinting platform NGB-RTM represents a major advancement in bioprinting capabilities, and we are thrilled to play a role in making these tools accessible to researchers across Germany. Our partnership is not just about business growth, it's about fostering innovation and contributing to scientific breakthroughs that can change the world.”
The NGB-R™ platform represents a revolutionary leap in bioprinting technology, offering unparalleled precision and flexibility for researchers in the fields of tissue engineering and regenerative medicine. Its state-of-the-art capabilities including Multimodality- Bioprinting Technology, patented LAB (Laser Assisted Bioprinting) Technology, In-Line Imaging, Zebr4D AI- assisted software etc., enable the production of complex, three-dimensional tissues to mimic the natural composition and functionality of human organs.
About HVD Life Science Vertriebs GmbH:
HVD Life Sciences is a marketing and distribution company that specializes in sourcing, supplying and supporting life science solutions. We bring a global perspective to our business worldwide, covering regions including Central and Southeast Europe, the Middle East, Africa, the Commonwealth of Independent States, and the Far East. We offer a wide range of high quality products from carefully selected manufacturers of innovative and industry-leading tools and technologies.
With all of our suppliers, we focus on building strong relationships that will ensure long-term success for our customers, our partners and ourselves.
https://www.hvdlifesciencesaustria.at/portfolio/poietis-4d-bioprinter/
https://hvdlifesciences.com/about-us.html
About Poietis:
Poietis is a health technology company specialized in the development and manufacturing of human tissues by bioprinting. Its main mission is to develop new therapeutic solutions based on its expertise in bioprinting technologies and in particular in high resolution laser bioprinting. Poietis has developed the Next Generation Bioprinting (NGB) platform, which is available in a research version for tissue bioengineering (NGB-RTM) and a clinical grade version (NGB-CTM) compatible with Good Manufacturing Practices for ATMPs and implantable bioprinted tissue production. This multimodal, robotic platform allows the fabrication of complex tissues while ensuring repeatability and reproducibility. Poietis' bioprinting technology is the result of innovative research conducted for over ten years at Inserm and the University of Bordeaux. Founded in September 2014, Poietis operates a portfolio of over 100 patents and currently employs 22 people.
For more information on the NGB-R™ bioprinting platform, please reach out to:
ngb-platform@poietis.com | www.poietis.com
This strategic partnership is anticipated to set new standards in the field of biotechnological research, providing scientists and researchers in Germany with access to state-of-the-art bioprinting technology. The Poietis’ NGB-R™ platform is expected to play a crucial role in advancing research in tissue engineering, regenerative medicine, and drug discovery, among other areas.
Dr. Peter Frost, CEO of PELOBIOTECH, expressed his passion for the partnership, stating, “Our alliance with HVD Life Science Vertriebs GmbH represents a significant leap forward not only for our two companies but for the entire field of biotechnological research in Germany. The Poietis’ NGB-RTM platform is at the top of bioprinting technology, enabling the creation of complex tissue structures with incredible precision. This technology has the potential to revolutionize fields from pharmaceutical testing to regenerative medicine.”
Echoing Dr. Frost's sentiments, Dr. Lothar Steeb, CEO & CSO of PELOBIOTECH, highlighted the impact this partnership would have on scientific discovery and innovation. “The distribution of Poietis’ NGB-RTM platform through our partnership, enables this revolutionary technology to be made available to innovative and outstanding researchers in Germany," said Dr. Steeb. "We are proud to contribute to the acceleration of research breakthroughs that can lead to major advances in healthcare and treatment modalities."
Werner Buergler, Sales Director of HVD Life Science Vertriebs GmbH, also commented on the new partnership, emphasizing the significance of bringing such advanced technology to the German market. “Our collaboration with PELOBIOTECH marks a pivotal moment in our mission to supply the scientific community with the most innovative and impactful technologies,” said Werner Buergler. “The Poietis’ Next-Gen Bioprinting platform NGB-RTM represents a major advancement in bioprinting capabilities, and we are thrilled to play a role in making these tools accessible to researchers across Germany. Our partnership is not just about business growth, it's about fostering innovation and contributing to scientific breakthroughs that can change the world.”
The NGB-R™ platform represents a revolutionary leap in bioprinting technology, offering unparalleled precision and flexibility for researchers in the fields of tissue engineering and regenerative medicine. Its state-of-the-art capabilities including Multimodality- Bioprinting Technology, patented LAB (Laser Assisted Bioprinting) Technology, In-Line Imaging, Zebr4D AI- assisted software etc., enable the production of complex, three-dimensional tissues to mimic the natural composition and functionality of human organs.
About HVD Life Science Vertriebs GmbH:
HVD Life Sciences is a marketing and distribution company that specializes in sourcing, supplying and supporting life science solutions. We bring a global perspective to our business worldwide, covering regions including Central and Southeast Europe, the Middle East, Africa, the Commonwealth of Independent States, and the Far East. We offer a wide range of high quality products from carefully selected manufacturers of innovative and industry-leading tools and technologies.
With all of our suppliers, we focus on building strong relationships that will ensure long-term success for our customers, our partners and ourselves.
https://www.hvdlifesciencesaustria.at/portfolio/poietis-4d-bioprinter/
https://hvdlifesciences.com/about-us.html
About Poietis:
Poietis is a health technology company specialized in the development and manufacturing of human tissues by bioprinting. Its main mission is to develop new therapeutic solutions based on its expertise in bioprinting technologies and in particular in high resolution laser bioprinting. Poietis has developed the Next Generation Bioprinting (NGB) platform, which is available in a research version for tissue bioengineering (NGB-RTM) and a clinical grade version (NGB-CTM) compatible with Good Manufacturing Practices for ATMPs and implantable bioprinted tissue production. This multimodal, robotic platform allows the fabrication of complex tissues while ensuring repeatability and reproducibility. Poietis' bioprinting technology is the result of innovative research conducted for over ten years at Inserm and the University of Bordeaux. Founded in September 2014, Poietis operates a portfolio of over 100 patents and currently employs 22 people.
For more information on the NGB-R™ bioprinting platform, please reach out to:
ngb-platform@poietis.com | www.poietis.com
